- Home
- CELH vs ROIV Comparison
CELH vs ROIV Comparison
Compare CELH & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELH
- ROIV
- Stock Information
- Founded
- CELH 2004
- ROIV 2014
- Country
- CELH United States
- ROIV United Kingdom
- Employees
- CELH N/A
- ROIV N/A
- Industry
- CELH Beverages (Production/Distribution)
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CELH Consumer Staples
- ROIV Health Care
- Exchange
- CELH Nasdaq
- ROIV Nasdaq
- Market Cap
- CELH 11.7B
- ROIV 7.8B
- IPO Year
- CELH N/A
- ROIV N/A
- Fundamental
- Price
- CELH $46.37
- ROIV $10.99
- Analyst Decision
- CELH Strong Buy
- ROIV Buy
- Analyst Count
- CELH 17
- ROIV 4
- Target Price
- CELH $47.24
- ROIV $17.50
- AVG Volume (30 Days)
- CELH 7.0M
- ROIV 7.3M
- Earning Date
- CELH 08-05-2025
- ROIV 08-07-2025
- Dividend Yield
- CELH N/A
- ROIV N/A
- EPS Growth
- CELH N/A
- ROIV N/A
- EPS
- CELH 0.32
- ROIV N/A
- Revenue
- CELH $1,329,198,000.00
- ROIV $29,053,000.00
- Revenue This Year
- CELH $60.22
- ROIV $2.64
- Revenue Next Year
- CELH $25.97
- ROIV $378.09
- P/E Ratio
- CELH $143.34
- ROIV N/A
- Revenue Growth
- CELH N/A
- ROIV N/A
- 52 Week Low
- CELH $21.10
- ROIV $8.73
- 52 Week High
- CELH $60.70
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- CELH 71.21
- ROIV 44.75
- Support Level
- CELH $45.37
- ROIV $10.83
- Resistance Level
- CELH $47.69
- ROIV $11.82
- Average True Range (ATR)
- CELH 1.49
- ROIV 0.32
- MACD
- CELH 0.09
- ROIV -0.07
- Stochastic Oscillator
- CELH 84.07
- ROIV 16.24
About CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages, Celsius Essentials line (containing aminos), Celsius On-the-Go powder packets, and the recently acquired portfolio of Alani Nu energy drinks and snacks. Celsius dedicates its efforts to branding and innovation, while it largely utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.